Skip to main content

Advertisement

Table 2 Patients’ characteristics according to dichotomized distribution of MPO in the overall cohort (n = 47)a

From: MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity

  MPO high MPO low p-value
n = 12 (100 %) n = 35 (100 %)
Age (median, range) 55 (45–73) 60 (34–77) 0.196
FIGO stage
 II 0 1 (2.9) 0.401
 IIIA 0 1 (2.9)
 IIIB 3 (25.0) 2 (5.7)
 IIIC 7 (58.3) 25 (71.4)
 IV 2 (16.7) 6 (17.1)
Residual disease
 None 4 (33.3) 12 (34.3) 0.919
 <2 cm 5 (41.7) 12 (34.3)
 >2 cm 3 (25.0) 10 (28.6)
Numbers of chemotherapy cycles
 <6 1 (8.3) 6 (17.1) 0.440
 6 or more 11 (91.7) 28 (80.0)
Primary cancer biopsies
 CSb 10 (83.3) 23 (65.7) 0.249
 CRb 2 (16.7) 12 (34.3)
Recurrent cancer biopsies (n = 10/35)
 CSb 9 (90.0) 23 (65.7) 0.135
 CRb 1 (10.0) 12 (34.3)
RFSc (mean/SE) 11.9 (2.7) 9.5 (1.6) 0.380
OSc (mean/SE) 56.8 (14.4) 39.3 (4.4) 0.139
  1. apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Chi-Square or the Fisher’s Exact test
  2. bCS chemosensitive, CR chemoresistant
  3. cRFS recurrence-free survival, OS overall survival